Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.


<< Back

Helen Ho, Ph.D.

Chief Business Officer

Helen brings more than 15 years of pharmaceutical and biotechnology industry experience with a strong track record in business development, corporate growth strategy and operations. She joined Blueprint Medicines in April 2018, most recently serving as Senior Vice President, Corporate Development accountable for business development, alliance management and new product planning. In her present role, she is responsible for driving the company’s corporate strategy, leading Business Development and Portfolio Strategy & Program Management. Prior to joining Blueprint Medicines, Helen served as Vice President, Head of Corporate Development at TCR2 Therapeutics. She led portfolio strategy, business development and investor & public relations which culminated in closing of $125M Series B crossover financing. Prior to TCR2 Therapeutics, Helen was the Director, Business Development & Operations at Agios Pharmaceuticals where she played a broad role in company building having led the business development licensing function, supported company’s IPO and building of its Rare Genetic Disorders and Immuno-Oncology franchises. Previously, Helen was a management consultant at L.E.K Consulting leading projects from both Boston and Shanghai offices. Helen holds a Ph.D. in Cell Biology from Yale University and B.S. in Biochemistry from University of California, Los Angeles.